Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model
Sumit Kumar(Leiden University Medical Center), Alfred C.O. Vertegaal(Leiden University Medical Center)
Cited by 125
Related Papers
In Vivo Identification of Human Small Ubiquitin-like Modifier Polymerization Sites by High Accuracy Mass Spectrometry and an in Vitro to in Vivo Strategy
|Molecular & Cellular Proteomics|2007|299
System-wide identification of wild-type SUMO-2 conjugation sites
|Nature Communications|2015|119
The poly-SUMO2/3 protease SENP6 enables assembly of the constitutive centromere-associated network by group deSUMOylation
|Nature Communications|2019|79
Global non-covalent SUMO interaction networks reveal SUMO-dependent stabilization of the non-homologous end joining complex
|Cell Reports|2021|75
SUMO targets the APC/C to regulate transition from metaphase to anaphase
|Nature Communications|2018|53